Eye implant approved by Scottish Medicines Consortium


Ozurdex has been accepted by the Scottish Medicines Consortium for use within the NHS in Scotland.

Ozurdex has been accepted by the Scottish Medicines Consortium for use within the NHS in Scotland.

Allergan announced the approval of the dexamethasone intravitreal implant for patients with macula oedema following central retinal vein occlusion (CRVO) and branch retinal vein occlusion (BRVO).

In a trial of 1000 patients Ozurdex was proven to increase vision by 15 letters or more on an eye chart in 29% of macular oedema patients. Some patients experienced these improvements for up to six months.

Patients in England and Wales already had access to Ozurdex, meaning the decision is important for Scottish macula oedema sufferers. Consultant ophthalmologist surgeon, Forth Valley NHS Trust, Mr Tariq Saboor, said, "The availability of a licensed, effective and now SMC accepted treatment is a significant step forward for management of RVO patients in Scotland. Having access to a treatment that tackles the significant inflammation and swelling resulting from blocked retinal veins is good news for my patients. The fact that the treatment only needs to be administered up to every 6 months is also a significant advantage.”

Recent Videos
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
Paulo Antonio Silva, Associate Professor of Ophthalmology at Harvard Medical School
Intraocular Pressure Outcomes Following Suprachoroidal Triamcinolone Acetonide in Patients With Glaucoma, Ocular Hypertension, or Steroid Response
Durga Borkar, MD, MMCi, discusses FAS inhibition with ONL-1204
Theodore Leng, MD, MS, speaks about 12-Month Real-World Clinical and Anatomical Outcomes With Faricimab in Patients With Diabetic Macular Edema:The FARETINA-DME Study
Rishi P. Singh, MD, discussed his presentation on the results from part 1 of the Phase 2/3 SIGLEC trial assessing AVD-104 for GA
Carl C. Awh, MD, FASRS, speaks with Hattie Hayes of Ophthalmology Times Europe
Carl J. Danzig, MD
Martin Zinkernagel, MD, PhD, speaks about the ASRS sustainability expert panel
Srinivas Sai Kondapalli, MD, discusses outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA
© 2024 MJH Life Sciences

All rights reserved.